Drug profile

The FDA adverse-event record for Plavix

15 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Plavix. See the species affected, top reactions, and outcomes below.

15
adverse-event reports
26.7%
death-coded share
Dog
most-reported species
5
Lethargy (see also Central nervous system depression in Neurological) - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
15
Total Reports
4
Deaths Reported
26.7%
Death Rate

Active Ingredients

Plavix

Administration Routes

OralUnknown

Species Affected

Dog 12
Cat 3

Most Affected Breeds

Domestic Shorthair 3
Dachshund - Standard Smooth-haired 2
Siberian Husky 2
Retriever - Golden 1
Unknown 1
Dachshund (unspecified) 1
Shiba Inu 1
Terrier - Bull - American Pit 1
Retriever - Labrador 1
Terrier - Jack Russell 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 5
Other abnormal test result NOS 3
Decreased appetite 3
Immune mediated haemolytic anaemia 3
Vomiting 3
Medication error NOS 3
Seizure NOS 2
Death by euthanasia 2
Lethargy (see also Central nervous system depression in 'Neurological') 2
Regenerative anaemia 2
Abnormal red blood cell 2
Diarrhoea 2

Outcome Breakdown

Ongoing
8 (53.3%)
Euthanized
4 (26.7%)
Recovered/Normal
2 (13.3%)
Recovered with Sequela
1 (6.7%)

Plavix Adverse Event Insights

15 reports name Plavix; 4 recorded a death outcome (26.7% of reported events, not a population-level mortality rate). Active ingredient: Plavix. Administration routes: Oral, Unknown.

By species: Dog (12 reports), Cat (3 reports). By breed: Domestic Shorthair (3), Dachshund - Standard Smooth-haired (2), Siberian Husky (2).

Leading clinical signs: Lethargy (see also Central nervous system depression in Neurological) (5), Other abnormal test result NOS (3), Decreased appetite (3), Immune mediated haemolytic anaemia (3). Outcome, 15 coded reports: Ongoing leads at 53.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.